Lexaria Bioscience Corp. Highlights DehydraTECH’s Potential in GLP-1 Industry

Kelowna, BC — Lexaria Bioscience Corp., a health care company specializing in pharmaceuticals, has announced that its DehydraTECH technology could significantly impact the GLP-1 industry by reducing side effects associated with leading drugs. This development comes as the GLP-1 sector, known for its rapid growth in weight loss and diabetes control, faces challenges with patient retention due to adverse effects.

DehydraTECH’s Role in Reducing Side Effects

DehydraTECH is recognized as the only publicly disclosed technology capable of reducing side effects across the top three GLP-1 drugs: semaglutide, tirzepatide, and liraglutide. These drugs are pivotal in the GLP-1 market, which saw revenues rise from $53.5 billion in 2024 to $70.1 billion in 2025, with projections reaching $156 billion by 2030. Despite this growth, a significant portion of users discontinue treatment due to gastrointestinal side effects, with 47-64% stopping within one to two years and 75.7% experiencing adverse events.

Strategic Collaborations and Market Impact

Lexaria is actively collaborating with a pharmaceutical partner, referred to as “PharmaCO,” under a material transfer agreement initiated in September 2024. This partnership aims to evaluate DehydraTECH compositions, potentially enhancing patient retention and supporting further industry growth.

Financial Overview

As of July 21, 2025, Lexaria Bioscience Corp. closed at $0.97 on the Nasdaq, with a market capitalization of $17,020,000. The company’s 52-week high was $4.38 on August 29, 2024, and its low was $0.794 on July 15, 2025. The price-to-earnings ratio stands at -1.31, reflecting the company’s current financial position.

Lexaria continues to innovate in drug delivery platforms, holding a substantial intellectual property portfolio and operating a licensed in-house research laboratory. For more information, visit Lexaria Bioscience’s website .